Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07186556
Status
Recruiting

Conditions

  • Brain Tumor Adult
  • Cancer
  • Fatigue

Eligibility Criteria

Sex
ALL
Age
18 Years - 39 Years
Healthy Volunteers
Not accepted

Interventions

  • Survivorship Education — BEHAVIORAL
    Participants will participate in discussions with a trainer via videoconference of any adverse events, resolving technical issues related to the activity tracker, and discussing survivorship topics using the NCI's Facing Forward Life After Cancer Treatment booklet. Participants will receive calls twice weekly during weeks 1-6 and once weekly during weeks 7-12
  • RISE-YA Intervention — BEHAVIORAL
    Participants will receive one-on-one energy conservation (EC) counseling, behavior coaching, and individualized, progressive strength and aerobic training exercises with a trainer via videoconference. Participants will receive calls twice weekly during weeks 1-6 and once weekly during weeks 7-12. Each call will last one hour. Participants will also receive prescriptions for self-led exercise sessions.

Study Details

The goal of this research study is to learn about the effects of the RISE-YA intervention on cancer-related fatigue in young adults who are brain cancer survivors.

Key Dates

First listed
Sep 22, 2025
Start date
Sep 9, 2025
Status verified
Aug 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2031

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Participant Group/Arm
    Participants will randomized at baseline stratifying by gender and CRF level
  • Experimental: Intervention Group
    Participants will randomized at baseline stratifying by gender and CRF level

Primary Outcome Measure

Cancer Related Fatigue [ Time Frame: Measured at T1 (baseline), T2 (12 weeks), and T3 (24 weeks) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
Michael Roth, MD
713-792-7751
Michael Roth, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

Related Studies